One-Stop Shopping (setravis)

[setravis]

Press Release Source: Endocare, Inc.


Endocare Stock to Commence Trading on NASDAQ
Tuesday October 9, 6:00 am ET


IRVINE, Calif., Oct. 9 /PRNewswire-FirstCall/ -- Endocare, Inc. (OTC Bulletin Board: ECRE - News), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that it has been approved for listing on NASDAQ. The Company's common stock will commence trading on The NASDAQ Capital Market under the symbol "ENDO" beginning tomorrow, October 10, 2007.


Craig T. Davenport, Endocare's Chief Executive Officer stated, "Our listing on NASDAQ is a significant milestone for Endocare, marking the completion of a long turnaround process. We believe that the NASDAQ listing should help us attract a broader audience of potential investors, resulting in a more liquid security and enhanced stockholder value over time."

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. These forward-looking statements include statements relating to the Company's listing on The NASDAQ Capital Market. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q and other filings with the U.S. Securities and Exchange Commission. Such risk factors include, but are not limited to, uncertainty regarding the effects of the listing of the Company's common stock on The NASDAQ Capital Market. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.


    Investor Contact:      Media Contact:        For Additional Information:
    Matt Clawson           Len Hall              Craig T. Davenport, CEO
    Allen & Caron, Inc.    Allen & Caron, Inc.   Michael R. Rodriguez, CFO
    (949) 474-4300         (949) 474-4300        Endocare, Inc.
    [email protected]    [email protected]    (949) 450-5400




--------------------------------------------------------------------------------
Source: Endocare, Inc.

[setravis]

(PGNX)
Progenics To Begin Ph II Trial of
Oral Methylnaltrexone
Progenics Pharmaceuticals, Inc. (PGNX) got a modest boost at
Monday's open after announcing plans with Wyeth (WYE) to begin
two Phase 2 clinical trials to evaluate daily dosing of oral methylnaltrexone
in patients with chronic, non-malignant pain who are being
treated with opioids and are experiencing opioid-induced constipation.
Each study will separately evaluate a different oral formulations of methylnaltrexone.
Both studies are expected to take approximately six months to complete.
Methylnaltrexone, an investigational drug, is being studied as a treatment for the peripheral side effects
of opioid analgesics. It is designed to mitigate the effect of opioids on peripheral receptors without interfering
with central nervous system pain relief. Methylnaltrexone is being developed in subcutaneous and
oral forms to treat opioid-induced constipation. Currently, there is no approved medication that specifically
targets the underlying cause of opioid-induced constipation.
Wyeth and Progenics have an exclusive, worldwide agreement for the joint development and commercialization
of methylnaltrexone for the treatment of opioid-induced side effects, including constipation
and post-operative ileus (POI), a prolonged dysfunction of the gastrointestinal (GI) tract following
surgery. Wyeth received worldwide rights to methylnaltrexone, and Progenics retained an option to
co-promote the product in the United States.
Adolor Corporation (ADLR), in collaboration with GlaxoSmithKline plc (GSK), is developing an opioid
antagonist, Entereg(TM) (alvimopan), for post-operative ileus, which has completed phase 3 clinical trials,
and for opioid-induced bowel dysfunction, which is in phase 3 clinical trials. Entereg is further along
in the clinical development process than methylnaltrexone, and Adolor has received an approvable letter
from the FDA for Entereg regarding the treatment of post-operative ileus.
Mundipharma International Ltd, an independent company associated with Purdue Pharma, has an oral
PR oxycodone/naloxone combination tablet that has been licensed in Germany under the trade name
TARGIN(R) for adult patients with severe chronic pain and opioid-induced constipation. Oral naloxone
reduces the impact of opioid-induced constipation, while having no effect on the analgesic efficacy of
oxycodone and minimal central effects. The drug will also be submitted for registration in other European
countries.
In addition to the development of methylnaltrexone, Progenics is developing a novel viral-entry inhibitor
for HIV. This molecule is designed to inhibit the virus' ability to enter certain types of immune system
cells. The Company has successfully completed a phase 1a study with PRO 140.
The Company is also developing immunotherapies for prostate cancer, including monoclonal antibodies
directed against prostate specific membrane antigen ("PSMA"), a protein found on the surface of prostate
cancer cells. Vaccines designed to stimulate an immune response to PSMA are conducted through
a joint venture with Cytogen Corporation (CYTO). Recent findings on PSMA structure and biology may
have important implications for other cancers as well. According to the Prostate Cancer Research Institute,
"Monoclonal antibodies are the closest thing we have found so far to 'magic bullets,' which can be
carefully targeted to reach specific sites."
A substantial portion of revenues to date has been derived from federal government grants and research
contracts. As of June 30, 2007, the Company had an accumulated deficit of $223.2 million and cash on
hand of $139.1 million.
In September, Wellington Management Company, LLP, on behalf of its clients, reported an 11.8% ownership
in the Company's stock. This was increase of 7.06% beneficial ownership on June 30, 2007.
Bank of America recently initiated coverage of PGNX at a Buy rating with a price target of $31.

[setravis]

▲TOP NEWS GAINERS.......

SYMBOL    CLOSE    %GAIN    VOLUME    NEWS

ANTP $10.520 +38.97% 2,968,700 Q1 EPS 8c vs (4c) EPS +300% Y/Y.

NIHK $0.106 +32.50% 11,999,700 $6M in Convertibles Finance Purchase of Eagle Broadband IPTV Asset.

APDN $0.155 +29.17% 842,700 Closes on Initial Rounds of Bridge Financing Totaling $550K.

AFT $1.110 +26.14% 109,200 Signs Two Year Supply Agreement Worth $68 Million.

ACGI $0.710 +18.33% 540,600 $3M Purchase in Convertibles at $5 by Vicis to Foster Acquisitions, Sales.

BIOF $5.240 +17.49% 495,100 Response to Falling Stock Price with Repurchase Plan of $7.5M Shares.

STRN $10.560 +17.28% 395,200 Q3 EPS 27c vs 9c EPS +200% Y/Y; Guidance Comments.

TELK $3.940 +13.87% 8,888,500 Soars on Monday After FDA Removes Partial Hold on TELCYTA(R) Trial.

EPLN $0.710 +12.70% 42,900 Q2 EPS 2c vs 1c EPS +100% Y/Y.

ORCT $8.660 +9.90% 488,400 Enters Settlement Agreement with Conexants Systems for $14.2M.

MSTR $87.070 +9.59% 768,100 SunTrust Ups to Buy from Neutral; Analyst Notes.

INSP $19.780 +9.10% 1,443,800 Announces Sale of Mobile Services Business.

YTEC $13.850 +3.20% 555,600 Subsidiary Acquires 100% of Recency Technology for $3.3M in Cash.

[setravis]

A quick look at today's biggest up and down movers.
Oct 22, 2007
Winners & Sinners: Goodman Global, China Direct, Dollar Tree...


Goodman Global (GGL) shares are flying this morning after news that the company will be purchased by private equity firm Hellman & Friedman for $26.50 per share.


Royal Caribbean Cruises (RCL) is also moving in the green this morning after handily beating earnings expectations.


China Techfaith Wireless (CNTF) is soaring today after receiving a contract from China`s Ministry of Public Security to exclusively develop pocket PC phones for Chinese police forces.


Yahoo (YHOO) is also moving up today after beating 3Q earnings estimates.


Steven Madden Ltd. (SHOO) shares are flying after reports that third parties have expressed interest in purchasing the NY-based shoe maker.


Tempur-Pedic (TPX) is also in the green after 3Q profits beat estimates by 4 cents per share.

<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>

Dollar Tree Stores (DLTR) shares are sliding after reports of its CFO resigning.


Also tumbling is Schering-Plough (SGP) after falling short of 3Q earnings expectations.


Thornburg Mortgage (TMA) is in the red this morning after disappointing earnings results and the cancellation of this quarter`s dividend payment.


Webmd (WBMD) is also to the downside after lowering its guidance for next quarter.

SanDisk Corp. (SNDK) is in the red this morning after disappointing investors with poor earnings results.

Schlumberger Ltd. (SLB) is also falling after lowering its outlook on natural gas processing. 

[setravis]

NEWS MOVERS.......

[setravis]

(DAIO).......
AFTER HOURS - TOP STORY
Data I/O Reports Q3 Results;
EPS 18c vs 1c EPS +1,700% Y/Y
Data I/O Corporation (DAIO) reported Q3 results ended September
2007. Q3 Revenues were $7.28M; up more than 6% from the same
period a year ago. Q3 EPS was 18c; up more than 1,700% from Q3 a
year ago. Shares of DAIO were up $1.98, or more than 49% in After
Hours, early on Wednesday evening.

[setravis]

AFTER HOURS HEADLINES.......

SYMBOL                                NEWS

BPEV            Approved for Exclusive Use of Brando Logo for Intl. Marketing.

RELL            Hires 25-Year Finance Expert Kathleen Dvorak as VP, CFO & CSO.

ATAR           Secures $10M Bluebay Credit Facility for Liquidity and Short
                   Term Biz Plan.

CGSE           Agrees to Realtime Navigation Project with Motorola; to Begin
                   Next Month.

XRIT            Completes $180M Acquisition of Pantone, Inc.

GFSI            David Glenn Stepping Down from Board.

CBZ             Acquiring Healthcare Business Resources.

PXG             Announces Organizational Re-alignment; Appoints Scott Sporrer
                   Interim CFO.

ARSD           Receives Approval for Joint Stock Company.

HF               Arranges Refinancing for Ballston Tower in Virginia.

GAI             Announces Intentions to Appeal SEB Patent Infringement Ruling.

[setravis]

(DAIO).......
AFTER HOURS - TOP STORY
Data I/O Reports Q3 Results;
EPS 18c vs 1c EPS +1,700% Y/Y
Data I/O Corporation (DAIO) reported Q3 results ended September
2007. Q3 Revenues were $7.28M; up more than 6% from the same
period a year ago. Q3 EPS was 18c; up more than 1,700% from Q3 a
year ago. Shares of DAIO were up $1.98, or more than 49% in After
Hours, early on Wednesday evening.

DAIO.......Update !
<><><><><><><><><><><><><><><><><><><><><><><><><>

Press Release Source: Data I/O Corporation


Data I/O Announces Third Quarter Profits
Wednesday October 24, 4:30 pm ET


REDMOND, Wash., Oct. 24 /PRNewswire-FirstCall/ -- Data I/O Corporation (Nasdaq: DAIO - News), the leading provider of manual and automated device programming systems, today announced financial results for the third quarter of 2007.


Revenues for the third quarter of 2007 were $7.3 million, an increase of 26% compared with $5.8 million for the second quarter of 2007. New orders during the third quarter were $8.3 million, up 33% from the $6.2 million for the second quarter of 2007. The gross margin as a percentage of sales for the third quarter of 2007 was 62.0%, compared with 49.1% for the second quarter of 2007. The increase in gross margin percentage was primarily due to a favorable product mix; higher sales volume relative to fixed operating costs; sales channel mix being mostly direct; and savings from our restructuring actions, as well as favorable inventory material cost and labor and overhead variances.

In accordance with U.S. generally accepted accounting principles (GAAP), net income for the third quarter of 2007 was $1.6 million, or $0.18 per share, compared with a net income of $47,000 or $0.01 per share for the third quarter of 2006, and compared with a net loss of ($1.1 million), or ($0.13) per share, for the second quarter of 2007. Included in the results of each of these periods was $0.01 per share related to the impact of expensing options.

"We were pleased to report both the large orders to a new automotive customer announced earlier, as well as strong sales to wireless customers", said Fred Hume, president and CEO. "The substantial increase reported in gross margin, which combined with savings resulting from our restructuring actions were the leverage for delivering outstanding profitability for the third quarter."

Conference Call Information

A conference call discussing the third quarter and 2007 financial results will follow this release today at 2:00 p.m. Pacific time/5:00 p.m. Eastern time. To listen to the conference call, please dial (480) 629-9025 passcode: DAIO. A taped replay will be made available approximately one hour after the conclusion of the call and will remain available for one week. To access the replay, please dial (320) 365-3844, access code: 891734. The conference call will also be simultaneously webcast over the Internet; visit the News and Events section of the Data I/O Corporation website at http://www.dataio.com to access the call from the site. This webcast will be recorded and available for replay on the Data I/O Corporation website approximately two hours after the conclusion of the conference call.

About Data I/O Corporation

Celebrating 35 years of innovative leadership in the device programming industry, Data I/O Corporation (Nasdaq: DAIO - News), offers expertise in delivering intellectual property to programmable devices, with integrated manufacturing solutions that specifically address the requirements of engineering and manufacturing customers. Data I/O Corporation has headquarters in Redmond, WA, with sales and services offices worldwide. For further information, visit the company's website at http://www.dataio.com.

--------------------------------------------------------------------------------
Source: Data I/O Corporation



52wk Range: 2.92 - 4.49
Volume: 1,083,113
Avg Vol (3m): 21,113.6

Technicals
Record Price High
Gap Up
Percentage Gainer

Last Price Quote is:
45.43%above 13-day MA
56.85%above 50-day MA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $34.79 
P/E Ratio: 2,941.18 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

[setravis]

Wednesday's Biggest Stock Stars.......
A little late in posting....but you can still follow 

[setravis]

Follow up on DAIO.......

[setravis]

AFTER HOURS HEADLINES.......

Symbol                                            News

[setravis]

AP
Stocks Rally As Credit Worries Remain
Tuesday November 6, 6:48 pm ET
By Madlen Read, AP Business Writer 
Stocks Jump As Investors Buy Bargains and Energy and Metals Producers; Credit Worries Remain


NEW YORK (AP) -- Wall Street bounded higher Tuesday as investors still mindful of widening credit problems nonetheless went in search of bargain stocks. The Dow Jones industrial average rose 117 points, with soaring oil and precious metals prices driving up the companies that produce those commodities.


Investors remain haunted by the big debt problems at banks, notably Citigroup Inc. and Merrill Lynch & Co. But companies outside of the banking, lending and housing industries have been posting strong financial results -- on Tuesday, Tenet Healthcare Corp., Nortel Networks Corp. and Archer Daniels Midland Co. impressed Wall Street with their quarterly earnings.

And with no major bad news to follow up Citigroup's Sunday announcement that it was preparing to mark down another $8 billion to $11 billion of subprime debt, even bank stocks, pummeled in recent months, looked like bargains.

Citigroup fell, but JPMorgan Chase & Co., Bank of America Corp., Wachovia Corp., Wells Fargo and Washington Mutual Inc. -- which all hit 52-week lows Monday -- each jumped Tuesday.

"There was an absence of bad news," said Jim Herrick, manager of equity trading at Baird & Co. "But there's room for another shoe to drop. I don't think we're out of the woods yet. It's a classic relief rally."

The Dow rose 117.54 or 0.87 percent, to 13,660.94. The size of the gain masked the nervousness in the market; stocks were earlier in the session.

Broader stock indicators also turned higher. The Standard & Poor's 500 index rose 18.10, or 1.20 percent, to 1,520.27, and the Nasdaq composite index rose 30.00, or 1.07 percent, to 2,825.18.

Government bonds dipped as money flowed back into stocks. The yield on the 10-year Treasury note, which moves opposite the price, rose to 4.37 percent from 4.34 percent late Monday. The yield rose to 4.38 percent in after-hours trading.

The Dow is about 500 points, about 3.5 percent, below the all-time high close of 14,164.53 it reached Oct. 9. Many companies, particularly in the technology and industrial sectors, have been consistently posting strong quarterly results, and appear undervalued. But third-quarter weakness in the financial sector -- the biggest in the S&P 500 -- has dragged down overall U.S. earnings growth.

"We've had a pretty good run, as far as a return for the year for the broad market indices," said Janna Sampson, director of portfolio management at Oakbrook Investments, pointing out that the S&P 500 index is up more than 8 percent for the year. "There may not be, given the level of earnings growth, a lot more for this quarter."

The dollar reached yet another record low against the euro. The 13-nation currency rose to a high of $1.4569 before pulling back slightly.

Crude oil on the New York Mercantile Exchange briefly passed $97 a barrel for the first time, before settling up $2.72 at a record $96.70. Gold on the Nymex rose to another 27-year high, settling up $12.60 $823.40 an ounce.

One of the most active stocks on the NYSE Tuesday was silver and gold miner Coeur d'Alene Mines Corp., which shot higher on higher metals prices and a Bear Stearns analyst's comment that the stock is underpriced. Shares climbed 52 cents, or 13.5 percent, to $4.36.

Exxon Mobil Corp., one of the 30 Dow components, was another big gainer, rising $2.72, or 3.1 percent, to $90.38.

Anthony Conroy, managing director at BNY ConvergEx Group, said it's a stock-picker's market. "If you do your due diligence, you can make money in the markets."

In earnings news, hospital operator Tenet Healthcare reported its third-quarter loss narrowed on higher charges and more admissions in commercial managed care. Tenet rose 72 cents, or 22.3 percent, to $3.95.

Nortel Networks said it swung to a profit in the third quarter despite lower revenue. The Canadian telecom equipment supplier reported its best operating margin since 2004. Nortel rose $2.90, or 17.8 percent, to $19.18.

Agricultural processor Archer Daniels Midland Co. said its fiscal first-quarter profit rose 9 percent as improved results at its oilseeds processing business offset higher corn prices. ADM rose $2.37, or 6.9 percent, to $36.89.

Advancing issues outnumbered decliners by about 7 to 4 on the New York Stock Exchange, where consolidated volume came to 3.77 billion shares, up from 3.75 billion on Monday.

The Russell 2000 index of smaller companies rose 11.34, or 1.43 percent, to 801.77.

Fed Chairman Ben Bernanke spoke in San Antonio Tuesday afternoon, but his prepared remarks did not address monetary policy or the direction of interest rates. Investors are awaiting his scheduled testimony Thursday before Congress' Joint Economic Committee.

Overseas, Japan's Nikkei stock average closed down 1.62 percent, while Hong Kong's Hang Seng index rose 1.71 percent a day after falling 5 percent. Britain's FTSE 100 rose 0.21 percent, Germany's DAX index rose 0.25 percent, and France's CAC-40 rose 0.44 percent.

New York Stock Exchange: http://www.nyse.com

Nasdaq Stock Market: http://www.nasdaq.com

[setravis]

Why we Love Wild Penny Stocks.......
Penny stocks have huge potential, that's their blessing and their curse.

The potential rewards are enormous. Just take a look at the 500% gain tiny Point Therapeutics (Nasdaq: POTP) has posted in a little more than a month or the recent spike in the stock price of adult entertainment provider Private Media (Nasdaq: PRVT).

Those jumps look like easy gains, considering that Deere (NYSE: DE) would have to add another $150 in value to double its share price, and Chipotle (NYSE: CMG) would need to throw another $120 on the fire to eke out another double.

Everybody loves pennies
It's the potential for quick gains in stocks like Point Therapeutics and Private Media that keep investors coming back. We typed "penny stocks" into Google, and the search engine spit out "about 825,000" hits. We did the same for more time-tested terms such as "blue-chip stocks" and "dividend-paying stocks" and got just 154,000 and 115,000 hits, respectively.

Sure, we expected a discrepancy, but the size of the gap was startling. It became even more interesting when we broke those hits down with Google Trends. According to Trends, penny stocks are particularly alluring to investors in Las Vegas, Tampa, Orlando, and Calgary -- the locales where the term is most often searched.

Las Vegas makes a bit of sense. Those folks are gamblers.

Florida, though? We hope the folks googling "penny stocks" down there aren't retirees.

Pay attention to the SEC's entire definition, not just the stock price. Going solely on price would wrongly categorize billion-dollar companies such as Atmel (Nasdaq: ATML) and Aquila (NYSE: ILA) as penny stocks.

Regardless, the SEC is spot-on when it says that true penny stocks are among the surest ways to lose money in the stock market.

So why do we love penny stocks?
We love penny stocks because they're fascinating. The world of pennies is inhabited by pumpers and dumpers, hypesters and scammers, and hardworking average Joes hoping to strike it rich. In pennies, the logic and reason that applies in the rest of daily life is replaced by zeal and prayer.

However, we don't love them enough to actually buy them. Yes, they have big potential. But their daily gyrations are unpredictable -- the stock price movements have next to nothing to do with the underlying company the stock represents. In fact, trading in pennies is highly illiquid, and prices are often manipulated by forces not at all related to the business.

The dangers of incredible promises
If you're buying stocks without paying attention to the business you're buying, you might as well buy a lottery ticket. Or, to use another analogy, you might as well buy up every baseball card of a benchwarmer on the Akron Aeros AA baseball team and hope that he someday rises up, fulfills his potential, and becomes an all-star for the big-league Cleveland Indians.

There's a better way
Before you conclude that the rest of the stock market is boring -- with big stocks such as IBM having a "big day" when they move up 1% or so -- let us introduce you to some underfollowed small caps. They're nothing like penny stocks, yet they offer some of the best returns on the market. Unlike penny stocks, promising small caps:

File reliable financial statements
Are transparent
Have conference calls individual investors can listen to
Don't simply hype their stock in press releases

That's a starting point. There are more -- and more important -- criteria to help you find great small-cap companies.

for instance, looks for a balance sheet with lots of cash and no debt, and a tenured CEO (or CEO/founder, if possible) who holds a substantial ownership stake in the business. In other words, we're looking for big returns with good, old-fashioned, bottom-up analysis.

[setravis]

(USBE) US BioEnergy Expanding Ethanol Production.......

Oil will undoubtedly be a conversational piece over the holiday break.
The older and younger generation will collectively curse the big oil
companies, the government, and whoever else they can pin the spiking
price upon.
The winter and holiday season have historically been times of cheaper crude and, in
turn, gasoline at the pump, but not so this year. The two have basically switched as
this past summer saw somewhat tame prices while the third quarter saw crude rally from $71 to over $80
and now to almost $100 a barrel. But gas prices haven't really correlated with crude over the past few
weeks. The effects are slowly but surely beginning to make that move.
With crude making the strong moves, it hasn't raised consumer awareness as much because of the lack
of correlation with the gas prices, but that will certainly change over the coming weeks, and with that in
mind, one needs to look at the alternate energy names much harder as the sleeping consumer will undoubtedly
take notice in the near future.
While the market has seen a downturn with many thinking a recession could be on the horizon, it could
be time to look for cheap names to protect against the inevitable pullback.
In the alternate energy space, one name to look into that could be considered cheap relative to peers is
US BioEnergy Corp (USBE). The Company is one of the many ethanol producers in the US. The Company
IPO'ed in mid Dec of 2006 in the $14 area and have since seen their share price slide to the $7's.
Currently, Archer-Daniels Midland Company is the largest player in the space but isn't a pure play. Some
of the other producers similar in size to USBE are Aventine Renewable Energy Holdings Inc. (AVR) and
VeraSun Energy Corporation (VSE).
Last week, USBE reported earnings that displayed some growth in both bottom line and production quarter
over quarter. During the third quarter of 2007, the company sold 73.2 million gallons of ethanol at an
average selling price of $1.76 per gallon, compared with 67.1 million gallons of ethanol at an average
selling price of $1.91 per gallon for the second quarter of 2007. Revenues were $151 million compared
to $154.4 million for the second quarter. Earnings were reported at 15c a share versus 12c a share in the
earlier period.
The top line production growth is also expected to continue over the coming months. Their Marion, South
Dakota facility is expected to being production in the first quarter of 2008 with a 110 million gallon a year
capacity. Their Hankinson, North Dakota facility is expected to being production in the second quarter
of 2008 with a 110 million gallon a year capacity. Their Dyersville, Iowa facility is expected to being
production in the second quarter of 2008 with a 110 million gallon a year capacity. And their Janesville,
Minnesota facility is expected to being production in the third quarter of 2008 with a 110 million gallon a
year capacity.
Over the next year, USBE will be adding 440 million gallons a year in production to bring their total to the
750 million gallon a year range. But it has been noted that acquisition is now cheaper than new facility
production evidenced by recent acquisitions by USBE and VSE in the $2.20 to $2.40 a gallon price
range.
With production expected to be in the 750 million gallon a year range and an acquisition price of $2.20
a gallon, the value could be in the $1.65 billion range. Now consider the market cap which is only $556
million and one can see the discrepancy.
Even in simple comparisons to similar firms, USBE could be considered a better value play. VeraSun has
more shares outstanding, more than double long term debt, very similar EBITDA and slightly higher revenue
in the trailing twelve months, but the stock is trading 40% higher. On just a production comparison,
USBE could easily be considered the better choice. The only real difference is the amount of cash VSE
has ($320M) versus USBE's ($80M). Even so, USBE hypothetically could issue $300 million in notes and
end up with more cash than VSE and still have less long term debt.
AVR has produced revenue of $1.62 billion in the trailing twelve months which is more than double compared
to USBE, but their EBITDA ($60M) was significantly less than what USBE produced ($79M) in the
past year. Also, AVR has $39 million in cash versus USBE's $79 million. Additionally, AVR's short term
debt is $48 million compared to USBE's of only $15.8 million. Long term debt is comparable at $331 million
versus AVR's $300 million.
While some fundamental numbers are better in AVR or VSE, the majority could be considerably point
towards USBE as being a better value. And with the expected production coming online in the next year,
the name is certainly one to follow. With that in mind, investors would be wise to watch.
ClipResmpa

[setravis]

Aftermarket News Has Three Names on the Move.......

Wednesday's session saw the indices rally on the back of jobs
data which was reported higher than analyst estimates. The job
growth displayed numbers which were in stark contrast of any
expectation of recession. Even so, fear and anxiety remained
with continued subprime talk on the horizon. Headlines were
reporting that the Bush administration was proposing a 5 year
interest rate freeze on owner occupied subprime mortgages. Large investment
firms were also reporting the receipt of subpoenas to testify before congress
on the selling of these risky debt securities. The fear and anxiety were still expected to be enough
to tip the scales in favor of a cut in the interest rates by the Fed next week.
But the real news came post-market on Bidz.com Inc. (BIDZ), Hoku Scientific (HOKU) and Novastar
Financial (NFI).
BIDZ has been battling a negative mention by Citron Research which was published last week.
The Company refuted the allegations made by Citron in a conference call that did more harm than
good to the share price. Following the report and call, shares were effectively been cut in half.
But it still didn't dissuade analysts from coming to its defense. Roth, Think Equity, and Craig-Hallum
all maintained a Buy rating in their reports and noted the weakness as entry opportunities.
Roth even commended the Company in its attempt to address the negative report after shares
dropped some $2.50 during the call.
Prior to the Citron report, BIDZ had issued guidance on November 27th of $180 million to $182
million in revenue for the 2007 fiscal year. Fourth quarter revenue was expected at $56 million
to $58 million. The reason for the raised guidance was noted as the record Thanksgiving holiday
weekend which saw a substantial jump. 2008 revenue guidance was also released which noted
expectations for $225 million to $230 million in revenue and 47c to 51c in earnings per share.
In aftermarket action on Wednesday, the Company updated their guidance. In a little more than
a week, the Company noted that it now expected revenue for the year to be at the higher end of
their $180 million to $182 million view. Pretax income for the year was guided for $18 million to
$18.5 million. Pretax income for the fourth quarter was expected to be $5.6 million to $6 million
on $56 million to $58 million.
Not much changed except the Company's expectation of 2007 revenue coming in at the higher
end of their range. That and the fact that televisions (one of the questions brought up in the conference
call regarding shill bidding) are no longer available on the site. Aftermarket trading saw
shares hit highs in the $13.00 range before falling back down to closing levels.
Hoku Scientific, a clean energy technology company, which has been gathering extravagant
amounts of prepayment contracts for polysilicon in hopes of gathering enough to construct a plant
in Idaho, announced that the Company had signed a non binding term sheet with Merrill Lynch
for $185 million in financing to facilitate the cost of construction. Following the announcement,
shares jumped to the $10.40 range after closing at $9.80.
Novastar Financial Inc. shares, which had been on many trader's screens following their recent
activity, saw another boost following the subprime mortgage lender's waiver acceptance by
Wachovia. At issue was the Company's adjusted tangible net worth which had fallen below the
convent levels. The Company originally broke the covenant on September 30th, but received a
waiver until November 30th. The Company now announced that Wachovia has until December
7th, this Friday. The first waiver was for 2 months. The second is now only 7 days which could
signify Wachovia is running short on patience. Even so, shares were up some 30% in after market
trade.
Wednesday's aftermarket session saw a plethora of exciting, market affecting news cause some
large swings in after hour trading. If the action continues to Thursday's session, investors would
certainly be wise to watch.